Gastrointestinal

Colorectal cancer: USPSTF screening modalities and intervals

Clinical Overview and When to Suspect Colorectal Cancer

— Iron deficiency anemia in any man or postmenopausal woman → colonoscopy mandatory

— Hematochezia, melena, or occult GI bleeding

— Change in bowel habits >6 weeks, narrow-caliber stools, tenesmus

— Unexplained weight loss, abdominal pain, or new constipation in adults ≥45

— Right-sided lesions: occult bleed + anemia; left-sided: obstructive symptoms, frank bleeding

— Family history of CRC or advanced adenoma in 1st-degree relative

— Personal history of adenomas, IBD (UC/Crohn colitis), abdominal radiation

— Hereditary syndromes: Lynch, FAP, MUTYH-associated polyposis, Peutz-Jeghers, juvenile polyposis

Colorectal cancer (CRC) is the 3rd most common cancer and 2nd leading cause of cancer death in the US, with rising incidence in adults <50 years — a trend that drove the 2021 USPSTF update lowering screening start age from 50 to 45.

Lifetime risk in average-risk adults is ~4–5%; ~70% of cases occur in those with no identifiable hereditary syndrome, making population screening the dominant prevention strategy.

Most CRCs arise via the adenoma–carcinoma sequence over 10–15 years, giving a long preclinical window ideal for screening. Serrated polyps account for ~15–30% via a parallel BRAF/CIMP pathway.

When to suspect CRC outside of screening:

Risk tiers that change screening approach (not USPSTF average-risk):

Board pearl: USPSTF screening recommendations apply only to asymptomatic average-risk adults. A 46-year-old with rectal bleeding does not get FIT — they get diagnostic colonoscopy. Screening tests are invalidated by symptoms.

Step 3 framing emphasizes the ambulatory decision: identify whether the patient is average-risk, increased-risk, or symptomatic, because each pathway has different modalities, intervals, and start ages.

Presentation Patterns and Key History

— Occult bleeding → iron deficiency anemia, fatigue, dyspnea on exertion

— Vague abdominal pain, palpable RLQ mass

— Late obstruction (lumen wider, stool more liquid)

— More likely MSI-high, especially in Lynch syndrome

— Hematochezia, change in stool caliber, constipation alternating with diarrhea

— Cramping, obstructive symptoms earlier

— Bright red blood per rectum, tenesmus, urgency, incomplete evacuation

— Often mistaken for hemorrhoids — DRE + anoscopy/colonoscopy required in any adult ≥45 with rectal bleeding

— Prior screening: modality, date, findings, polyp pathology

— Family history: number of relatives with CRC/advanced adenomas, ages at diagnosis, Lynch-spectrum cancers (endometrial, ovarian, gastric, urothelial, small bowel)

— Personal: IBD duration and extent, prior abdominal/pelvic radiation, hereditary syndrome testing

— Lifestyle: smoking, alcohol, obesity, red/processed meat, physical activity

Most screen-detected CRCs are asymptomatic — the entire rationale for screening. Symptomatic presentations typically indicate more advanced disease and worse prognosis.

Right-sided (cecum, ascending) tumors:

Left-sided (descending, sigmoid) tumors:

Rectal tumors:

Key history elements at every well visit ≥45:

Key distinction: A patient who reports "I had a colonoscopy 5 years ago, all normal" at age 55 is on schedule (10-year interval). A patient who had "polyps removed" requires the pathology report — tubular adenoma <10 mm vs. villous/high-grade dysplasia vs. sessile serrated lesion drives the next interval.

Board pearl: New-onset iron deficiency anemia in a man or postmenopausal woman is colon cancer until proven otherwise — bidirectional endoscopy (EGD + colonoscopy), not a FIT test. Step 3 stems use this to test whether you recognize symptomatic vs. screening pathways.

Physical Exam Findings (and Risk Assessment)

— Pallor, conjunctival rim pallor (anemia)

— Cachexia, temporal wasting in advanced disease

— Lymphadenopathy: left supraclavicular (Virchow), periumbilical (Sister Mary Joseph) in metastatic disease

— Palpable mass (RLQ for cecal, LLQ for sigmoid)

— Hepatomegaly or nodular liver → metastases

— Ascites, distension; high-pitched bowel sounds suggest partial obstruction

— Mandatory in any patient with rectal bleeding, tenesmus, or change in bowel habits

— Palpate for rectal mass within ~7–8 cm of anal verge; assess fixation, sphincter tone

— Note: DRE is not a screening test and does not replace colonoscopy or FIT

— Mucocutaneous pigmentation (lips, buccal) → Peutz-Jeghers

— Osteomas, epidermoid cysts, desmoids, CHRPE → Gardner variant of FAP

— Sebaceous adenomas/carcinomas → Muir-Torre (Lynch variant)

— Macrocephaly, mucocutaneous papules → PTEN/Cowden

CRC is often a physical-exam-poor disease in screen-eligible patients; a normal exam does not lower pretest probability when symptoms are present.

General:

Abdominal exam:

Digital rectal exam (DRE):

Skin/mucosal clues to hereditary syndromes:

Performance status assessment (ECOG/Karnofsky) — critical for staging-appropriate workup and treatment tolerance, especially in elderly patients where it drives screening cessation decisions.

Step 3 management: When evaluating a 60-year-old with iron deficiency anemia, document DRE findings, abdominal exam, and lymph node survey before ordering colonoscopy — these findings change staging urgency (e.g., palpable rectal mass → expedited MRI rectum + CT chest/abdomen/pelvis, not just colonoscopy alone).

Board pearl: A fixed, hard rectal mass on DRE in a patient with rectal bleeding is rectal cancer until histology proves otherwise — biopsy via flexible sigmoidoscopy and MRI pelvis for local staging are next steps, not stool-based testing.

USPSTF Screening Modalities — Stool-Based Tests

— High-sensitivity guaiac FOBT (gFOBT): annual; detects heme peroxidase; requires dietary restriction (avoid red meat, vitamin C, NSAIDs, peroxidase-rich foods); 3 cards from 3 separate stools; largely supplanted by FIT

— Fecal immunochemical test (FIT): annual; detects human globin; no dietary restriction; single stool sample; sensitivity for CRC ~74%, advanced adenoma ~24%; preferred stool-based test

— Multi-target stool DNA-FIT (sDNA-FIT, Cologuard): every 1–3 years (USPSTF) — typically every 3 years in practice; detects KRAS mutations, methylated BMP3/NDRG4, hemoglobin; sensitivity for CRC ~92%, advanced adenoma ~42%; higher false-positive rate than FIT

— Any positive FIT, gFOBT, or sDNA-FIT mandates diagnostic colonoscopy, not repeat stool testing

— Failure to perform follow-up colonoscopy negates the entire screening benefit and is a patient safety quality measure (HEDIS, MIPS)

— Time to colonoscopy after positive FIT should be ≤6 months (ideally ≤3); delays >10 months increase CRC incidence and mortality

USPSTF (2021) gives Grade A for ages 50–75 and Grade B for ages 45–49 for CRC screening in average-risk adults. Grade C (selective) for 76–85; no screening ≥86. All approved modalities are acceptable; the best test is the one the patient will complete.

Stool-based options:

Critical operational point — a positive stool-based test is NOT a diagnosis:

Step 3 management: A 52-year-old completes FIT — positive. Next step: schedule diagnostic colonoscopy, not repeat FIT in a year, not Cologuard, not CT colonography. Document shared decision-making and ensure closed-loop follow-up.

Board pearl: Stool-based screening intervals only apply if prior tests were negative AND the patient remains asymptomatic. Any GI symptom converts the workup to diagnostic, bypassing screening algorithms entirely.

USPSTF Screening Modalities — Direct Visualization Tests

— Visualizes entire colon; allows simultaneous polyp detection and removal (diagnostic + therapeutic in one session)

— Highest sensitivity for advanced adenomas and CRC

— Requires full bowel prep, sedation, day off work, escort home

— Risks: perforation ~1/1000, bleeding ~3/1000 (higher with polypectomy), sedation complications

— Quality metrics: adenoma detection rate (ADR) ≥30% men/≥20% women, cecal intubation ≥95%, withdrawal time ≥6 min

— Requires bowel prep; no sedation

— Lesions ≥6 mm → referral for colonoscopy

— Detects extracolonic findings (incidentalomas — both benefit and harm)

— Not ideal if patient has many comorbidities making follow-up colonoscopy risky

— Every 5 years alone, OR

— Every 10 years + annual FIT (combination strategy)

— Examines only to splenic flexure; misses right-sided lesions (a problem given the rising proportion of right-sided cancers, especially in women and Lynch patients)

— Limited prep, no sedation

Colonoscopy — every 10 years (the reference standard):

CT colonography (virtual colonoscopy) — every 5 years:

Flexible sigmoidoscopy:

Colon capsule endoscopy — every 5 years (USPSTF added in 2021): used when colonoscopy incomplete or contraindicated; requires prep

Key distinction: Screening colonoscopy intervals (every 10 years if normal) differ from surveillance colonoscopy intervals (after polyp removal or in IBD), which are dictated by USMSTF post-polypectomy guidelines — e.g., 1–2 tubular adenomas <10 mm → repeat in 7–10 years; 3–4 adenomas → 3–5 years; ≥5 adenomas or any ≥10 mm/villous/high-grade dysplasia → 3 years.

Board pearl: If colonoscopy is chosen and normal, the patient is "done" for 10 years — Step 3 stems test whether you incorrectly reorder FIT in the interim ("belt and suspenders" is wrong and not cost-effective in average-risk patients).

Risk Stratification — Average vs. Increased vs. High Risk

— No personal history of CRC, advanced adenoma, or IBD

— No family history of CRC or advanced adenoma in 1st-degree relative

— No known hereditary CRC syndrome

— No prior abdominal/pelvic radiation

— 1 first-degree relative with CRC or advanced adenoma at age <60, OR ≥2 FDRs at any age → start colonoscopy at age 40 or 10 years before youngest affected relative, whichever is earlier; repeat every 5 years

— 1 FDR with CRC or advanced adenoma at age ≥60 → start at age 40, screen as average risk (any modality, standard intervals)

— Lynch syndrome (HNPCC): colonoscopy every 1–2 years starting age 20–25 (or 2–5 years before youngest case); plus endometrial/ovarian surveillance, urinalysis, upper endoscopy

— Classical FAP: annual flexible sigmoidoscopy or colonoscopy starting age 10–15; colectomy when polyposis becomes unmanageable

— Attenuated FAP, MUTYH-associated polyposis: colonoscopy every 1–2 years starting age 18–20 (AFAP) or 25–30 (MAP)

— Peutz-Jeghers, juvenile polyposis: specialized regimens

— Surveillance colonoscopy with chromoendoscopy/biopsies 8 years after diagnosis of UC or Crohn colitis (or at diagnosis for PSC + UC), then every 1–3 years

— 76–85: Grade C — individualize based on overall health, prior screening history, life expectancy (≥10 years), and patient preference

— ≥86: do not screen

USPSTF average-risk criteria (start 45, stop 75):

Increased risk — modify start age and interval (NOT USPSTF, follow USMSTF/ACG):

High risk — hereditary syndromes:

Inflammatory bowel disease:

Stopping screening — USPSTF:

Step 3 management: Always ask "is this patient average risk?" before selecting a modality. A 38-year-old whose father had CRC at 52 is NOT average risk — start colonoscopy at age 40 (10 years before 52, but not later than 40), repeat every 5 years. USPSTF doesn't apply here.

Board pearl: Lowering start age to 45 (2021) is average-risk only; family-history and hereditary protocols are unchanged and start earlier.

Choosing the Modality — Shared Decision-Making

— Higher pretest probability (family history, prior adenomas)

— Willing/able to undergo prep, sedation, escort, day off

— Wants longest interval (10 years) and one-and-done convenience

— Anticoagulation can be managed periprocedurally

— Prefers non-invasive, home-based, annual cadence

— Limited access to endoscopy (rural, uninsured/underinsured)

— Wishes to avoid sedation risks

— Must accept that positive FIT mandates colonoscopy — counsel up front

— Non-invasive, every 3 years

— Higher per-test sensitivity but higher false-positive rate → more unnecessary colonoscopies; also more expensive

— Cannot tolerate sedation or has incomplete prior colonoscopy

— Accepts extracolonic incidental findings

— Risks/benefits of each modality

— Required interval and what positive results mean

— Patient's stated preference and chosen test

— Plan for follow-up and reminders

USPSTF endorses no single preferred modality — emphasizes that screening any eligible adult with any approved test is far better than non-screening with the "perfect" test. Adherence drives benefit.

Patient factors favoring colonoscopy:

Patient factors favoring FIT:

Patient factors favoring sDNA-FIT (Cologuard):

Patient factors favoring CT colonography:

Counseling script elements (document in chart):

Step 3 management: When a patient declines colonoscopy, offer FIT annually, not "no screening." This is both a USPSTF-aligned safety net and a quality measure. Document the discussion — it satisfies shared decision-making for value-based care metrics (HEDIS COL).

Board pearl: The cost-effective, adherence-maximizing answer on Step 3 is usually annual FIT when colonoscopy is refused — not Cologuard, not gFOBT, not "wait until they change their mind."

Post-Polypectomy and Post-Cancer Surveillance Intervals

— <10 mm, no dysplasia: 5–10 years

— ≥10 mm or with dysplasia: 3 years

— Traditional serrated adenoma: 3 years

— Clearing colonoscopy preoperatively or within 3–6 months post-op if obstructing

— Colonoscopy at 1 year, then 3 years, then every 5 years if normal

— CEA every 3–6 months × 2 years, then every 6 months × 3 years (stage II–III)

— CT chest/abdomen/pelvis annually × 5 years (stage II–III)

— H&P every 3–6 months × 2 years, then every 6 months × 3 years

Once a polyp or cancer is found, the patient leaves the USPSTF screening pathway and enters surveillance (USMSTF 2020 guidelines):

Normal colonoscopy, average risk: repeat in 10 years

Hyperplastic polyps <10 mm, rectosigmoid: 10 years (treated as normal)

1–2 tubular adenomas <10 mm: 7–10 years

3–4 tubular adenomas <10 mm: 3–5 years

5–10 adenomas <10 mm: 3 years

Any adenoma ≥10 mm, villous/tubulovillous, high-grade dysplasia: 3 years

>10 adenomas on single exam: 1 year; consider hereditary syndrome workup

Piecemeal resection of sessile polyp ≥20 mm: 6 months for site check

Sessile serrated lesions:

Post-CRC resection surveillance (NCCN/ASCO):

Step 3 management: A 60-year-old had sigmoid adenocarcinoma resected 1 year ago — next steps: surveillance colonoscopy now, CEA, and CT C/A/P. Not "back to USPSTF screening every 10 years."

CCS pearl: Order CEA before initial cancer resection (baseline), then trend post-op; a rising CEA warrants imaging for recurrence even with normal colonoscopy.

Board pearl: Surveillance intervals are not USPSTF — they are risk-stratified by histology and number/size of polyps. Memorize: 1–2 small TA = 7–10y; advanced features = 3y; >10 = 1y + genetics.

Special Populations — Elderly and Renal/Hepatic Impairment

— Life expectancy ≥10 years (use ePrognosis or similar tools)

— Prior screening history — a never-screened 78-year-old in good health derives more benefit than a 78-year-old screened normally at 75

— Comorbidity burden, functional status, patient values

— Procedural risk tolerance (sedation, bowel prep, hospitalization risk)

— Bowel prep: avoid sodium phosphate preps (risk of acute phosphate nephropathy, hyperphosphatemia) in CKD, elderly, heart failure, on ACEi/ARB/diuretics — use PEG-based preps (GoLYTELY, MiraLAX-Gatorade)

— Adjust sedation: lower midazolam/fentanyl in eGFR <30

— Contrast for CT colonography: standard kidney-protective measures if eGFR <30

— Coagulopathy increases polypectomy bleeding — check INR, platelets; correct INR <1.5, platelets >50k for routine; >80k for high-risk polypectomy

— Avoid benzodiazepines/opioids in advanced cirrhosis (encephalopathy risk) — propofol with anesthesia support preferred

— Variceal screening EGD may be combined with colonoscopy under same sedation

— Aspirin: continue for screening colonoscopy

— Clopidogrel/DOACs/warfarin: hold per ASGE guidance; bridge only if high thrombotic risk (mechanical mitral valve, recent VTE)

Ages 76–85 (USPSTF Grade C): Selective screening based on:

Ages ≥86: Do not screen — competing mortality outweighs benefit; harms (perforation, complications of incidentalomas, downstream procedures) predominate.

Frailty assessment: Use gait speed, grip strength, or Clinical Frailty Scale; frail older adults rarely benefit from screening regardless of chronologic age.

Renal impairment:

Hepatic impairment:

Anticoagulation/antiplatelet periprocedural management:

Step 3 management: An 80-year-old with CKD stage 4 due for screening — assess life expectancy and frailty first; if appropriate, use PEG prep, not NaP, and document shared decision-making.

Board pearl: Stopping age is biological, not chronological — a vigorous 78-year-old may screen; a frail 70-year-old with dementia and CHF should not.

Special Populations — Pregnancy, Younger Adults, and Demographic Subgroups

— Routine CRC screening is deferred during pregnancy unless symptomatic (rectal bleeding mistakenly attributed to hemorrhoids in pregnant patients delays diagnosis — maintain suspicion).

— Symptomatic evaluation: flexible sigmoidoscopy in 2nd trimester is preferred when feasible; colonoscopy reserved for strong indication (bleeding with anemia, suspected mass, IBD flare).

— Avoid ionizing radiation (CT colonography contraindicated); MRI without gadolinium is acceptable for staging if cancer confirmed.

— USPSTF does not recommend routine screening <45 in average-risk adults.

— Symptomatic young adults (rectal bleeding, iron deficiency anemia, persistent change in bowel habits): diagnostic colonoscopy — early-onset CRC is rising and frequently missed because clinicians anchor on hemorrhoids or IBS.

— Family history starting age 40 or earlier (10 years before youngest affected FDR).

— Higher CRC incidence and mortality, earlier age of onset.

— Some societies (ACG) historically recommended starting at age 45 even before 2021 USPSTF update; USPSTF now aligns at 45 for all average-risk adults regardless of race.

— Address structural barriers — insurance, transportation, mistrust — to improve completion.

— Genetic counseling and testing before screening cascade.

— Surveillance starts in adolescence or young adulthood per syndrome.

— Cascade testing for at-risk relatives is an ethical obligation discussed with the proband.

— Surveillance colonoscopy with chromoendoscopy 8 years after diagnosis (immediate at PSC + UC diagnosis).

Pregnancy:

Adults <45:

African American patients:

Hereditary syndrome carriers (Lynch, FAP, etc.):

IBD patients:

Step 3 management: A 35-year-old with 6 months of rectal bleeding and unintentional 15-lb weight loss — order colonoscopy now, not FIT, not "reassurance for hemorrhoids," not "screen at 45." Early-onset CRC is a board favorite.

Board pearl: USPSTF screening guidelines presuppose asymptomatic, average-risk. Pregnancy, symptoms, syndromes, and IBD all carve out separate pathways.

Complications and Adverse Outcomes — Screening Harms and Missed Cancers

— Perforation: ~0.5–1 per 1000 diagnostic; higher with polypectomy

— Post-polypectomy bleeding: ~1–6 per 1000; can present up to 14 days post-procedure

— Sedation complications: aspiration, hypotension, cardiopulmonary events (~5 per 10,000)

— Post-colonoscopy syndrome: abdominal pain, fever — distinguish from microperforation

— Splenic injury, infection: rare

— Radiation exposure (~5–8 mSv per study) — cumulative risk if repeated every 5 years

— Extracolonic findings in ~5–15% leading to downstream workup, some unnecessary

— False positives → unnecessary colonoscopies and procedural risk

— False negatives → false reassurance, delayed diagnosis (interval cancers)

— sDNA-FIT specificity (~87%) lower than FIT (~95%); more downstream colonoscopies per cancer detected

— Cancers diagnosed between screening exams; account for ~3–9% of CRCs after colonoscopy

— Causes: missed polyps, incomplete polypectomy, biology (serrated pathway, MSI-H tumors progress faster), poor prep, low ADR

— Mitigation: high-quality endoscopy (adequate prep, cecal intubation, ≥6-min withdrawal, ADR benchmarks)

— Failure to follow up positive FIT — the dominant system-level harm; closed-loop tracking is essential

— Failure to communicate pathology results, surveillance intervals, or hereditary syndrome workup

Screening is not benign — every test has potential harms that must be weighed in shared decision-making.

Colonoscopy harms:

CT colonography:

Stool-based tests:

Interval cancers:

Patient safety failures:

Step 3 management: Post-colonoscopy patient presents 4 days later with diffuse abdominal pain, fever, peritonitis → upright/CT abdomen for free air, NPO, IV fluids, broad-spectrum antibiotics, urgent surgical consult for perforation.

Board pearl: A "negative colonoscopy" 3 years ago in a now-symptomatic patient is not protective — repeat colonoscopy for new GI symptoms regardless of prior screening interval.

When to Escalate — Symptomatic Findings and Urgent Pathways

— Brisk hematochezia with hemodynamic instability (orthostasis, tachycardia, hypotension): resuscitate, type & cross, urgent GI consult

— Bowel obstruction from a likely tumor (vomiting, distension, no flatus, air-fluid levels on imaging): NG decompression, IV fluids, surgery consult, CT abdomen/pelvis

— Perforation post-colonoscopy: surgical emergency

— Severe anemia (Hb <7, or <8 with symptoms): transfuse, admit, expedited bidirectional endoscopy

— New iron deficiency anemia in man or postmenopausal woman → bidirectional endoscopy

— Positive FIT or sDNA-FIT → diagnostic colonoscopy within 3–6 months (ideally ≤3)

— Palpable rectal or abdominal mass → colonoscopy with biopsy, staging CT, MRI pelvis if rectal

— Suspected hereditary syndrome (multiple polyps, strong family history): referral to genetic counseling

— Gastroenterology: all positive screens, IBD surveillance, hereditary syndrome surveillance

— Colorectal surgery: confirmed cancer, large/complex polyps not amenable to endoscopic resection, prophylactic colectomy in FAP

— Medical oncology: stage II high-risk, stage III, IV CRC

— Radiation oncology: locally advanced rectal cancer (neoadjuvant chemoRT)

— Genetics: Lynch, FAP, MAP suspicion; Amsterdam II or Bethesda criteria met; universal MMR/MSI testing on all CRC tumors

Screening is an outpatient longitudinal activity, but several findings demand same-day or expedited escalation:

Immediate ED/inpatient triage:

Expedited outpatient (within days–2 weeks):

Specialty referrals:

CCS pearl: For a CCS case of suspected obstructing colon cancer: order CT abdomen/pelvis with contrast, CBC, CMP, type & screen, CEA baseline, place NG tube, IV fluids, NPO, surgical consult. Advance the clock 4–6 hours, reassess, then proceed to operative planning.

Board pearl: A positive screening test is not an emergency, but it becomes a missed opportunity if not followed up within ~6 months — Step 3 questions hammer the closed-loop follow-up.

Key Differentials — Other GI Causes of Same Symptoms

— Hemorrhoids/anal fissure: bright red, on toilet paper, painful with fissure; never the final diagnosis without excluding CRC in age-appropriate patients

— Diverticular bleeding: painless, large-volume, often left-sided; usually self-limited; colonoscopy needed

— Angiodysplasia: elderly, right-sided, recurrent occult or overt bleeding; associated with aortic stenosis (Heyde syndrome), CKD, vWD

— Ischemic colitis: lateral colon, watershed (splenic flexure), elderly with vascular disease; bloody diarrhea + abdominal pain

— IBD (UC, Crohn): bloody diarrhea, urgency, weight loss, extraintestinal manifestations; younger patients

— Infectious colitis: Shigella, EHEC, C. difficile, CMV — stool studies first

— IBS: Rome IV criteria; diagnosis of exclusion in patients ≥45 or with alarm features

— Diverticular disease, microscopic colitis, thyroid disease, medications (opioids, anticholinergics)

— Upper GI sources: peptic ulcer, gastric cancer, esophagitis, celiac disease

— Menstrual losses (premenopausal women) — but do not skip colonoscopy if symptoms, age ≥45, or family history

— Malabsorption (celiac), poor intake

— Diverticulitis, appendicitis, ovarian pathology, IBD, mesenteric ischemia, pancreatic cancer

Many conditions mimic CRC symptoms; the test-taker must avoid both over-screening (workup for non-CRC GI complaints) and under-screening (anchoring on benign diagnoses).

Hematochezia/rectal bleeding differential:

Change in bowel habits:

Iron deficiency anemia:

Abdominal pain:

Key distinction: Hemorrhoids and CRC coexist commonly — finding hemorrhoids on DRE does not exclude CRC. Always proceed to colonoscopy in age-eligible or symptomatic patients.

Board pearl: Iron deficiency anemia with positive FIT in a 50-year-old: do colonoscopy AND upper endoscopy (bidirectional) — ~10–15% have synchronous upper GI sources.

Key Differentials — Non-GI and Systemic Mimics

— Anemia of chronic disease/inflammation: normal/high ferritin, low TIBC, low transferrin saturation

— Hemolysis: elevated LDH, low haptoglobin, indirect hyperbilirubinemia, reticulocytosis

— Hematologic malignancy: MDS, multiple myeloma, leukemia

— Renal: EPO deficiency in CKD

— Nutritional: B12, folate deficiency (macrocytic, not microcytic)

— Hyperthyroidism, diabetes, malabsorption (celiac, pancreatic insufficiency)

— Other malignancies (pancreatic, gastric, lung, lymphoma, ovarian)

— Depression, dementia, social/economic food insecurity

— Chronic infections (TB, HIV)

— Ovarian cancer (esp. in women), uterine fibroids

— Lymphoma, GIST, sarcoma

— Abscess, hematoma, hernia

— Renal/adrenal masses

— Lymphoma, breast, lung, head/neck, gastric (Virchow node), testicular cancers

— Hepatocellular carcinoma, cholangiocarcinoma

— Pancreatic, breast, lung, neuroendocrine metastases

— Hemangioma, FNH, adenoma (benign)

— Hydatid cyst, abscess

— Migratory thrombophlebitis (Trousseau)

— Acanthosis nigricans (also gastric)

— Dermatomyositis (any visceral malignancy)

Symptoms attributed to CRC may originate outside the colon — Step 3 stems test breadth of differential.

Anemia without GI bleeding:

Weight loss/cachexia differential:

Abdominal/pelvic mass:

Lymphadenopathy:

Liver lesions (often the way metastatic CRC presents):

Paraneoplastic clues to CRC:

Key distinction: Microcytic anemia in adults ≥45 → think GI blood loss (CRC, gastric); macrocytic anemia → B12/folate, MDS, hypothyroidism, alcohol. Do not order screening colonoscopy for macrocytic anemia.

Board pearl: Trousseau syndrome (migratory superficial thrombophlebitis) classically associates with pancreatic adenocarcinoma but also occurs with CRC, gastric, and lung cancers — prompts hypercoagulable malignancy workup, not just routine screening.

Secondary Prevention and Long-Term Risk Reduction

— Physical activity: ≥150 min/week moderate aerobic; reduces incidence ~20–25%, reduces recurrence/mortality in survivors

— Weight management: BMI 18.5–24.9; obesity raises CRC risk, especially in men

— Diet: high fiber (whole grains, legumes, fruits/vegetables), limit red meat (<500 g/wk) and processed meats; consider Mediterranean dietary pattern

— Alcohol: limit to ≤1 drink/day women, ≤2/day men; less is better

— Tobacco cessation: smoking is a known CRC risk factor — leverage 5 A's, NRT, varenicline, bupropion

— Aspirin: USPSTF 2022 — no longer routinely recommends aspirin solely for CRC prevention; decision should be individualized for CV risk in adults 40–59 with ≥10% 10-year ASCVD risk, considering bleeding risk; do not initiate ≥60 solely for primary prevention

— Calcium, vitamin D: not recommended for CRC prevention based on evidence

— Postmenopausal hormone therapy: reduces CRC risk but harms outweigh benefits — not used for prevention

— Surveillance per Chunk 8

— Address financial toxicity, fatigue, ostomy care, sexual dysfunction, neuropathy (oxaliplatin), bowel dysfunction (LARS after rectal resection)

— Vaccinations: influenza annually, pneumococcal, COVID, RSV (age-eligible), HZV

— Manage cardiovascular risk — survivors die more often of CV disease than recurrence

— Lynch carriers: consider daily aspirin (CAPP2 trial showed reduced CRC); risk-reducing hysterectomy/BSO post-childbearing

— FAP: prophylactic colectomy (timing individualized); upper GI surveillance for duodenal/ampullary cancer

Beyond screening, modifiable factors reduce CRC incidence and recurrence — counsel at every preventive visit.

Lifestyle interventions (Grade B–C evidence):

Pharmacologic chemoprevention:

Survivorship after CRC treatment:

Genetic-informed prevention:

Step 3 management: A 65-year-old CRC survivor 2 years out — order surveillance colonoscopy/CEA/CT, but also address smoking, BMI, statin/BP for CV prevention, vaccines, and screen for depression. Long-term survivorship is multidisciplinary.

Board pearl: USPSTF dropped aspirin as a CRC-prevention recommendation in 2022 — do not start aspirin solely to prevent CRC.

Follow-Up, Monitoring, and Counseling Cadence

— Colonoscopy normal: next visit at 10 years for repeat; counsel symptoms warranting earlier evaluation

— FIT negative: annual reminder system; auto-mail kits, EMR registry tracking

— sDNA-FIT negative: 3 years

— CT colonography or sigmoidoscopy: per modality interval

— Establish a patient registry of all panel patients age 45–75

— Track screening status (modality, date, due date)

— Use outreach (mailed FIT kits, patient portal, phone) to close gaps — improves uptake more than office-based reminders alone

— Track positive FIT follow-through as a safety metric — target colonoscopy within 60–90 days

— Confirm symptoms (red flags vs. screening status)

— Review family history annually — new cancers in relatives can change risk category

— Document modality choice and shared decision-making

— Provide written prep instructions; teach-back method

— Importance of completing the FIT (sample technique, mailing, expiration dates)

— Bowel prep adherence — split-dose prep is standard for colonoscopy/CTC

— What to expect after sedation (no driving, no contracts, no childcare alone × 24 hours)

— When to call: bleeding > a few drops, severe pain, fever, vomiting, new abdominal distension

— HEDIS COL: % of eligible adults 45–75 screened

— MIPS quality measures include CRC screening rates

— Closed-loop notification of positive results is a Joint Commission patient-safety priority

Average-risk, baseline screening completed:

Quality improvement / panel management:

Counseling at each touchpoint:

Patient education priorities:

Health systems metrics:

Step 3 management: Patient declined colonoscopy 3 years ago at age 50, no follow-up — at this visit, revisit screening, offer FIT, document barriers, and arrange a reminder. Do not document "patient refused" without re-offering at subsequent visits.

Board pearl: Population health and panel management questions on Step 3 favor outreach + multiple modality options + closed-loop tracking as the right answer over physician-only counseling.

Ethical, Legal, and Patient Safety Considerations

— Disclose risks (perforation, bleeding, sedation, missed lesions), benefits, alternatives (FIT, sDNA-FIT, CT colonography), and consequences of not screening

— Patient must be able to provide informed consent before sedation — confirm comprehension, not just signature; if cognitively impaired, involve surrogate decision-maker

— Required for modality choice — document patient values, preferences, chosen test, and follow-up plan

— Particularly emphasized for 76–85 age range where harm/benefit is closer

— Failure to follow up positive FIT is the most common screening-related safety failure; institutions are increasingly liable for missed CRC after a positive screen with no follow-up colonoscopy

— Closed-loop result reporting: ordering clinician must confirm receipt of positive result and patient acknowledgment

— Handoffs between PCP, GI, surgery, oncology require explicit responsibility assignment for surveillance — "who is tracking the next colonoscopy?"

— Universal tumor MMR/MSI testing for all CRC patients — but counseling and downstream germline testing require informed consent for genetic testing, with attention to insurance discrimination (GINA covers health insurance, not life/disability/long-term care)

— Cascade testing: proband should be encouraged to share genetic results with at-risk relatives; clinician cannot disclose to relatives without consent (privacy) but can provide patient with shareable materials

— Disparities in CRC screening completion by race, insurance, geography → mailed FIT programs and patient navigators improve equity

— Discuss out-of-pocket costs: positive non-colonoscopy screen mandates follow-up colonoscopy, which under ACA must be covered without cost-sharing (clarified in 2022) — patients should not be billed for the follow-up colonoscopy

Informed consent for screening colonoscopy:

Shared decision-making:

Transition-of-care risks (Step 3 favorite):

Genetic testing ethics:

Mandatory reporting: Cancer diagnoses are reportable to state cancer registries — typically handled by pathology/institution, not individual clinician; no patient consent required, but transparency is best practice.

Equity and access:

Step 3 management: A 58-year-old's FIT returned positive 8 months ago; no follow-up arranged. Apologize transparently, schedule colonoscopy urgently, perform root-cause analysis of the tracking failure, and report to institutional patient safety. Disclosure of error is ethically required.

Board pearl: ACA coverage now includes follow-up colonoscopy after positive non-colonoscopy screen as a preventive service — no patient cost-sharing.

High-Yield Associations and Rapid-Fire Clinical Facts

— Colonoscopy: every 10 years

— CT colonography: every 5 years

— Flex sig alone: every 5 years; flex sig + annual FIT

— FIT: annual

— gFOBT (high sensitivity): annual

— sDNA-FIT (Cologuard): every 1–3 years (typically 3)

— Colon capsule: every 5 years

— Lynch: MLH1, MSH2, MSH6, PMS2, EPCAM

— FAP: APC gene, chromosome 5q

— MUTYH: biallelic, AR

Start age: 45 (USPSTF 2021, Grade B) for average-risk; 50–75 = Grade A; 76–85 = Grade C (individualize); ≥86 = no

Modalities and intervals (memorize):

Family history rule: 1 FDR <60 OR ≥2 FDRs any age → start at age 40 or 10 years before youngest case (whichever earlier), colonoscopy every 5 years

Lynch surveillance: colonoscopy q1–2y starting age 20–25

FAP surveillance: annual sig/colonoscopy starting age 10–15

IBD surveillance: start 8 years after diagnosis of UC/Crohn colitis (immediately at diagnosis if PSC); every 1–3 years

Streptococcus gallolyticus (bovis) bacteremia/endocarditis → colonoscopy to evaluate for occult CRC

Clostridium septicum bacteremia → colon cancer association

Right-sided cancers: anemia, MSI-H, Lynch; left-sided: obstruction, hematochezia, APC/KRAS

Tumor markers: CEA for monitoring, not screening or diagnosis; CA 19-9 not for CRC

Universal testing: all CRC tumors → MMR/MSI testing to screen for Lynch

Genetics:

Cancers up to 50% risk in Lynch: endometrial, colon, ovarian, gastric, urothelial, small bowel, biliary

Quality benchmarks: ADR ≥30% men/≥20% women; cecal intubation ≥95%; withdrawal ≥6 min

Aspirin for CRC prevention: no longer routinely recommended (USPSTF 2022)

Board pearl: Step 3 favors the precise combination of age 45, average risk, FIT annually OR colonoscopy every 10 years, with shared decision-making documented — this single sentence answers most stems.

Board Question Stem Patterns

— Answer: Offer screening; FIT annual OR colonoscopy q10y (or any USPSTF option); shared decision-making

— Trap: "Wait until 50" (outdated) or "do nothing" (wrong)

— Answer: Colonoscopy (diagnostic, not screening)

— Trap: FIT, sDNA-FIT, "reassure as hemorrhoids" — all wrong

— Answer: Colonoscopy now (or at 40, whichever first), repeat every 5 years

— Trap: "Start at 45" (USPSTF doesn't apply to increased risk)

— Answer: Schedule diagnostic colonoscopy now; closed-loop safety issue; do not repeat FIT

— Answer: Offer screening with shared decision-making (Grade C); reasonable to screen

— Trap: "Do not screen" because age >75 — wrong if individualized indications

— Answer: Surveillance colonoscopy now (5–7 years per USMSTF) — not USPSTF q10y

— Answer: Bidirectional endoscopy (colonoscopy + EGD); not just FIT

— Answer: Colonoscopy to evaluate for occult CRC

— Answer: Surveillance colonoscopy now with biopsies (chromoendoscopy), q1–3y

— Answer: Refer to genetic counseling; tumor MMR/MSI testing; consider Lynch syndrome

— Answer: Offer annual FIT (or other approved alternative); document

— Answer: Do not screen

Pattern 1 — "Asymptomatic 45-year-old, no family history, no symptoms":

Pattern 2 — "55-year-old with rectal bleeding":

Pattern 3 — "38-year-old, father had CRC at 50":

Pattern 4 — "Patient had FIT positive 4 months ago, hasn't followed up":

Pattern 5 — "78-year-old, never screened, healthy, life expectancy >10 years":

Pattern 6 — "Patient had 2 small tubular adenomas removed 5 years ago":

Pattern 7 — "Iron deficiency anemia in 60-year-old man":

Pattern 8 — "Strep gallolyticus endocarditis":

Pattern 9 — "Patient with UC × 8 years":

Pattern 10 — "Multiple polyps + family history of CRC and endometrial":

Pattern 11 — "Patient refuses colonoscopy":

Pattern 12 — "Asymptomatic 86-year-old":

Step 3 management: Read the stem twice for age, symptoms, family history, prior polyp pathology, and IBD/syndrome status — these four elements determine 90% of CRC screening questions.

Board pearl: When in doubt between FIT and colonoscopy, the patient's preference (shared decision-making) is often the correct answer on Step 3.

One-Line Recap

For asymptomatic average-risk adults, USPSTF recommends colorectal cancer screening from age 45 to 75 (Grade B 45–49, Grade A 50–75; Grade C individualized 76–85; none ≥86), using any of: annual FIT, annual high-sensitivity gFOBT, sDNA-FIT every 1–3 years, flexible sigmoidoscopy every 5 years (or every 10 years with annual FIT), CT colonography every 5 years, or colonoscopy every 10 years — with any positive non-colonoscopy test mandating diagnostic colonoscopy.

— Start at 45 (changed in 2021) for average-risk asymptomatic adults; stop at 75 routinely, individualize 76–85, none ≥86

— Symptoms or increased risk = diagnostic colonoscopy, not screening — never substitute FIT for evaluation of bleeding, anemia, or change in bowel habits

— Family history rule: 1 FDR <60 or ≥2 FDRs → colonoscopy at age 40 (or 10 years before earliest case), repeat every 5 years

— Hereditary syndromes (Lynch q1–2y from 20–25; FAP annual from 10–15) and IBD (8 years post-diagnosis, then q1–3y) follow separate protocols

— Surveillance after polyps is per USMSTF histology-based intervals, not USPSTF — advanced features → 3 years; 1–2 small TAs → 7–10 years

— Positive FIT or sDNA-FIT must be followed by colonoscopy within ~3 months — closed-loop tracking is the dominant patient-safety pearl

— Aspirin is no longer routinely recommended for CRC prevention (USPSTF 2022)

— Shared decision-making, panel management, and outreach (mailed FIT kits, patient navigators) drive equitable, value-based screening — the test-favored framework on Step 3

High-yield rapid recap: